VT-122 is a multi-targeted, low-cost, investigational combination drug therapy.
VT-122 is an orally administered combination of propranolol, a non-selective beta adrenergic receptor blocker, and etodolac, a COX2 selective enzyme inhibitor. Propranolol suppresses autonomic nervous system hyper-activation and excess catecholamine release associated with systemic inflammation. Etodolac targets key cell signaling and inflammatory pathways in the tumor, liver and immune system.
VT-122 Attenuation of Systemic Inflammation
VT-122 Inhibition of Signaling Cascade Cross-Talk
By synergistically targeting multiple pathways, VT-122 is designed to attenuate cancer-induced systemic inflammation and thereby reverse cachexia, lengthen duration of treatment, improve quality-of-life and extend survival.